Related Experiment Video
Updated: Sep 4, 2025

Passive Administration of Monoclonal Antibodies Against H. capsulatum and Others Fungal Pathogens
Published on: February 14, 2011
A case of immune complex type hemolytic anemia induced by initial micafungin administration
Hiroto Ishii1, Tomohiko Sato2, Miyuki Ishibashi2
1Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
Abstract:
We report the first case of immune complex type hemolytic anemia by initial micafungin administration that was given as prophylaxis to a 42-year-old Japanese man receiving chemotherapy for primary amyloidosis. The few cases found in the literature were associated with secondary administration causing immune hemolytic attacks. Despite its rarity, the present case calls for increased awareness of micafungin-induced hemolytic anemia upon initial administration.
Insights
Micafungin can cause immune complex hemolytic anemia, even upon initial use. This rare side effect requires greater clinical awareness, especially in patients undergoing chemotherapy.
Area of Science:
- Hematology
- Pharmacology
- Immunology
Background:
- Primary amyloidosis treatment often involves chemotherapy.
- Antifungal prophylaxis, such as with micafungin, is common during chemotherapy.
- Immune hemolytic anemia is a rare but serious adverse drug reaction.
Observation:
- A 42-year-old Japanese man developed immune complex hemolytic anemia.
- This reaction occurred after the initial administration of micafungin.
- The patient was receiving chemotherapy for primary amyloidosis.
Findings:
- This is the first reported case of micafungin-induced hemolytic anemia upon initial administration.
- Previous literature documented similar reactions only after secondary administration.
- The mechanism involves immune complex formation triggered by micafungin.
Implications:
- Clinicians should be aware of the potential for micafungin to cause hemolytic anemia early in treatment.
- Monitoring for signs of hemolytic anemia is crucial in patients receiving micafungin, particularly during chemotherapy.
- This case highlights the importance of considering drug-induced immune hemolytic anemia even with initial drug exposure.
Related Concept Videos
Hypersensitivities
Types of Hypersensitivities
Hypersensitivity reactions are categorized into four types: Type 1, Type 2, Type 3, and Type 4. Each type has a distinct mechanism...
Fungal Phylum Microsporidia
Allergic Drug Reactions
Immunodeficiency Diseases
There are three main causes of immunodeficiency...

